Pilot controlled trial of the adherence readiness program: An intervention to assess and sustain hiv antiretroviral adherence readiness

AIDS and Behavior

Volumn 17, Issue 9, 2013, Pages 3059-3065

  Wagner, Glenn J ^a   Lovely, Paul ^b   Schneider, Stefan ^b  

^a RAND CORPORATION   (United States)

^b Living Hope Clinical Foundation   (United States)

Author keywords

Adherence; HIV; Intervention; Practice trials; Readiness

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIRECTIVE COUNSELING; DRUG SELF ADMINISTRATION; FEMALE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICATION COMPLIANCE; METHODOLOGY; PILOT STUDY; PROGRAM EVALUATION; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CALIFORNIA; COGNITIVE THERAPY; DIRECTIVE COUNSELING; FEMALE; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; PILOT PROJECTS; PROGRAM EVALUATION; SELF ADMINISTRATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84889098283     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-013-0550-9     Document Type: Article

References (12)

1. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20(2):223-31.
2. Bouton MEM. A learning theory perspective on lapse, relapse, and the maintenance of behavior change. Health Psychol. 2000;19(1):57-63.
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
4. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
5. Bangsberg DR, Hecht FM, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26(5):435-42.
6. Grimes RM, Grimes DE. Readiness, trust, and adherence: a clinical perspective. J Int Assoc Physicians AIDS Care. 2012 Aug 17; ahead of print.
7. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(1):S23-35.
8. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285-97.
9. Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE. Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol. 1996;15(2):114-23.
10. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.
11. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-3.
12. Gill C, Sabin L, Hamer D, et al.(2010) Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 8 Jan 2010;14(4):785-793.